Foamix Pharmaceuticals (NASDAQ:FOMX) and Aurora Cannabis (NYSE:ACB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.
This is a breakdown of recent ratings and target prices for Foamix Pharmaceuticals and Aurora Cannabis, as reported by MarketBeat.com.
Foamix Pharmaceuticals currently has a consensus target price of $17.67, suggesting a potential upside of 333.01%. Given Foamix Pharmaceuticals’ higher probable upside, research analysts clearly believe Foamix Pharmaceuticals is more favorable than Aurora Cannabis.
Insider and Institutional Ownership
62.8% of Foamix Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Aurora Cannabis shares are held by institutional investors. 3.3% of Foamix Pharmaceuticals shares are held by company